Loading company…
Merrimack Pharmaceuticals develops oncology and human growth hormone therapies.
Founded in 1993 and based in Cambridge, US, Merrimack Pharmaceuticals develops therapies including Onivyde®, an FDA-approved treatment for metastatic pancreatic cancer. In 2025, the company shifted focus toward human growth hormone therapies. It went public in March 2012, raising USD 100 mn through its IPO.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in